{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:13:12Z","timestamp":1782879192048,"version":"3.54.5"},"reference-count":54,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Usage of automated insulin delivery systems is increasing for the treatment of people with type 1 diabetes (T1D). This study compared long-term cost-effectiveness of the Advanced Hybrid Closed Loop MiniMed 780G (AHCL) system versus sensor augmented pump (SAP) system with predictive low glucose management (PLGM) or multiple daily injections (MDI) plus intermittently scanned continuous glucose monitoring (isCGM) in people with T1D in Greece.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Analyses were performed using the IQVIA CORE Diabetes Model, with clinical input data sourced from various studies. In the AHCL versus SAP plus PLGM analysis, patients were assumed to have 7.5% baseline glycated hemoglobin (HbA1c), when comparing AHCL with MDI plus isCGM baseline HbA1c was assumed to be 7.8%. HbA1c was reduced to 7.0% following AHCL treatment initiation but remained at baseline levels in the comparator arms. Analyses were performed from a societal perspective over a lifetime time horizon. Future costs and clinical outcomes were discounted at 1.5% per annum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>AHCL was associated with increased quality-adjusted life expectancy of 0.284 quality-adjusted life years (QALYs) and EUR 10,173 lower mean total lifetime costs with SAP plus PLGM. Compared with MDI plus isCGM, AHCL was associated with increased quality-adjusted life expectancy of 2.708 QALYs, EUR 76,396 higher mean total lifetime costs, and an incremental cost-effectiveness ratio of EUR 29,869 per QALY. Extensive sensitivity analysis confirmed the robustness of results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Over patient lifetime, the MiniMed 780G system is likely to be\n                      <jats:italic toggle=\"yes\">cost saving<\/jats:italic>\n                      compared with the SAP plus PLGM system and\n                      <jats:italic toggle=\"yes\">cost-effective<\/jats:italic>\n                      compared with MDI plus isCGM in people with T1D in Greece.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2021.0443","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T07:29:38Z","timestamp":1640676578000},"page":"316-323","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece"],"prefix":"10.1177","volume":"24","author":[{"given":"Vaia","family":"Lambadiari","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, Research Institute and Diabetes Center, Attikon University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli Zeynep","family":"Ozdemir Saltik","sequence":"additional","affiliation":[{"name":"Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"de Portu","sequence":"additional","affiliation":[{"name":"Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ida","family":"Buompensiere","sequence":"additional","affiliation":[{"name":"Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Kountouri","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Research Institute and Diabetes Center, Attikon University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Korakas","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Research Institute and Diabetes Center, Attikon University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-9858","authenticated-orcid":false,"given":"Helen","family":"Sharland","sequence":"additional","affiliation":[{"name":"Ossian Health Economics and Communications, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-1795","authenticated-orcid":false,"given":"Ohad","family":"Cohen","sequence":"additional","affiliation":[{"name":"Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.06.018"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12408"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1188823"},{"key":"e_1_3_4_5_2","unstructured":"Kanavos P van den Aardweg S Schurer W: Diabetes expenditure burden of disease and management in 5 EU countries. LSE Health London School of Economics. 2012. https:\/\/www.lse.ac.uk\/business-and-consultancy\/consulting\/assets\/documents\/diabetes-expenditure-burden-of-disease-and-management-in-5-eu-countries.pdf (accessed June22 2021)."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2012.03.002"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14225"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S006"},{"key":"e_1_3_4_9_2","first-page":"145","article-title":"Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control","volume":"38","author":"McCall AL","year":"2013","unstructured":"McCall AL, , Farhy LS: Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control. Min Endocrinol, 2013; 38:145\u2013163.","journal-title":"Min Endocrinol"},{"key":"e_1_3_4_10_2","unstructured":"World Health Organization: Diabetes Fact Sheet. April 13 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes (accessed June8 2021)."},{"key":"e_1_3_4_11_2","unstructured":"World Health Organization: Global report on diabetes. World Health Organization. 2016. https:\/\/apps.who.int\/iris\/handle\/10665\/204871 (accessed June8 2021)."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0930"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12676"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/db20-97-LB"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2250"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32514-9"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2015.0324"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30150-0"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1604"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2020.05.010"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05263-9"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31535-5"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.02.028"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X1980"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X2006"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.07.007"},{"key":"e_1_3_4_29_2","unstructured":"Data on file: Medtronic pivotal trial \u201cCIP321 Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System Clinical Study Report: Data Analysis for Subjects 14\u201375 Years Old\u201d Revision A."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1610"},{"key":"e_1_3_4_31_2","unstructured":"Data on file: Analysis of the Pivotal trial raw data; of the HbA1c improvement for users with different baseline HbA1c levels."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.2337\/db20-68-OR"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/618039"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.03.003"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0410-2"},{"key":"e_1_3_4_36_2","unstructured":"German Federal Ministry of Health: Inability to work: work and days after diagnoses. 2017. https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Geschaeftsergebnisse\/AU-Faelle-nach-nach-Diagnosen_2017.pdf (accessed April21 2022)."},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-90"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-4-251"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-014-0712-x"},{"key":"e_1_3_4_40_2","unstructured":"N\u00f8rgaard K Scaramuzza A Bratina N et al.: Sensor-augmented pump therapy in real-life: patients reported outcomes results of the INTERPRET observational study. Abstract 1058. Berlin Germany; 2012."},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0288"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X115757"},{"issue":"2","key":"e_1_3_4_43_2","first-page":"A","article-title":"Real-world outcomes of the first 1\u2019000 users of the MiniMed\u2122 780G system","volume":"23","author":"Da Silva J","year":"2021","unstructured":"Da Silva J, , Arrieta A, , Castaneda J, et al.: Real-world outcomes of the first 1\u2019000 users of the MiniMed\u2122 780G system. Diabetes Technol Therap, 2021; 23(S2):A-18.","journal-title":"Diabetes Technol Therap"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.12.015"},{"key":"e_1_3_4_45_2","unstructured":"Nationella Diabetesregistret: https:\/\/www.ndr.nu\/#\/knappen (accessed July13 2020)."},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0031"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2007.05.003"},{"key":"e_1_3_4_48_2","first-page":"3","article-title":"Fear of hypoglycemia: a review","volume":"5","author":"Gonder-Frederick L","year":"2013","unstructured":"Gonder-Frederick L: Fear of hypoglycemia: a review. Diabetic Hypoglycemia, 2013; 5:3\u201311.","journal-title":"Diabetic Hypoglycemia"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2015.1045815"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1139\/apnm-2020-0461"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.12658"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1080\/15402002.2019.1647207"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.9.2262"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0345"},{"key":"e_1_3_4_55_2","unstructured":"Svensson A-M Eliasson B Linder E et al.: Nationella Diabetesregistret [National Diabetes Register]\u2014nationwide results 1996\u20132020. 2021. https:\/\/www.ndr.nu\/pdfs\/NationWideResults_1996-2019.pdf (accessed November9 2021)."}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2021.0443","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:13:27Z","timestamp":1777400007000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2021.0443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1089\/dia.2021.0443"],"URL":"https:\/\/doi.org\/10.1089\/dia.2021.0443","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}